L-DOPA

• UNSPSC Description:

  L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

• Target Antigen:

  Dopamine Receptor; Endogenous Metabolite

• Type:

  Natural Products

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/L-DOPA.html

• Purity:

  99.98

• Solubility:

  0.1 M HCL : 20 mg/mL (ultrasonic;warming;adjust pH to 2 with HCl;heat to 60°C)|DMSO : 2 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 1 mg/mL (ultrasonic)

• Smiles:

  N[C@@H](CC1=CC(O)=C(C=C1)O)C(O)=O

• Molecular Weight:

  197.19

• References & Citations:

  [1]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[2]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.|[3]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[4]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.|[5]M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194(1):66-75. |[6]Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993(1-2):54-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  Launched

• CAS Number:

  59-92-7